Press release
Benign Prostatic Hyperplasia (BPH) Market to Reach USD 18.4 Billion by 2034
Benign Prostatic Hyperplasia
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70812
The BPH market is undergoing a shift toward less invasive procedures, improved drug formulations, and precision diagnostics, making it an attractive and evolving segment within the urology and men's health industry.
Market Overview
The global BPH market was valued at USD 10.6 billion in 2024 and is projected to reach USD 18.4 billion by 2034, expanding at a CAGR of 5.8%.
Key Market Highlights
• Aging population significantly increasing disease incidence.
• Growing preference for minimally invasive surgical techniques over traditional open surgery.
• Availability of effective pharmacological therapies such as alpha-blockers, 5-alpha-reductase inhibitors, and combination drugs.
Challenges
• Side effects associated with long-term drug use.
• Limited awareness in low-income regions.
• Reimbursement barriers in certain healthcare systems.
Segmentation Analysis
By Treatment Type
• Pharmacological Therapies
o Alpha-Blockers
o 5-Alpha-Reductase Inhibitors
o Combination Therapy
• Minimally Invasive Surgical Therapies (MIST)
o Transurethral Microwave Thermotherapy (TUMT)
o Transurethral Needle Ablation (TUNA)
o Prostatic Urethral Lift (PUL)
o Rezūm Water Vapor Therapy
• Surgical Procedures
o Transurethral Resection of the Prostate (TURP)
o Open Prostatectomy
o Laser Therapies (HoLEP, GreenLight)
By End-User
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
Summary:
Pharmacological treatments remain first-line therapy, but minimally invasive surgical approaches are experiencing rapid adoption due to quicker recovery times and reduced complications.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70812/benign-prostatic-hyperplasia-market
Regional Analysis
North America
• Largest share due to high diagnosis rates, advanced treatment infrastructure, and strong insurance coverage for BPH procedures.
• Widespread adoption of laser and PUL procedures.
Europe
• Germany, France, and the UK lead in MIST adoption.
• Increasing government support for early diagnosis programs.
Asia-Pacific
• Fastest-growing market due to large aging male population, rising awareness, and growing access to urology care in China, India, and Japan.
• Expanding use of affordable generic drugs.
Latin America
• Brazil and Mexico driving regional growth with improved healthcare spending and physician training programs.
Middle East & Africa
• Growth in urban centers with rising adoption of imported medical devices; rural access remains limited.
Summary:
While North America and Europe dominate in adoption, Asia-Pacific presents the greatest growth opportunity through population demographics and healthcare modernization.
Market Dynamics
Key Growth Drivers
• Rising prevalence of BPH due to aging populations.
• Expanding use of minimally invasive surgical techniques.
• Technological advancements in laser and imaging systems.
• Growing availability of combination drug therapies.
Key Challenges
• Drug side effects and patient adherence issues.
• Limited access to advanced devices in developing countries.
• Regulatory approval delays for innovative devices.
Latest Trends
• Integration of imaging guidance in BPH surgeries.
• AI-based symptom assessment and treatment planning.
• Outpatient-based procedures gaining traction.
• Development of novel drug delivery systems to reduce side effects.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70812
Competitive Landscape
Major Players
• Boston Scientific Corporation
• Teleflex Incorporated
• Olympus Corporation
• Lumenis Ltd.
• Richard Wolf GmbH
• Karl Storz SE & Co. KG
• GlaxoSmithKline plc (GSK)
• Sanofi S.A.
• Abbott Laboratories
• Eli Lilly and Company
Competitive Strategies
• Mergers and acquisitions to expand device portfolios.
• Launch of next-generation laser platforms and water vapor therapies.
• Partnerships with hospitals for physician training in MIST techniques.
Conclusion
The BPH market is positioned for robust growth as medical technology, surgical innovation, and patient-centric care converge. The transition toward less invasive, highly effective treatments will define the market's trajectory, offering both clinical and economic benefits.
Key Takeaways:
• Pharmacological therapies dominate early-stage treatment, but MIST is rapidly expanding.
• North America remains the largest market, while Asia-Pacific is the fastest-growing.
• Technological innovation and accessibility will be key drivers of market expansion.
This report is also available in the following languages : Japanese (良性前立腺肥大症市場), Korean (양성 전립선 비대증 시장), Chinese (良性前列腺增生市场), French (Marché de l'hyperplasie bénigne de la prostate), German (Markt für benigne Prostatahyperplasie), and Italian (Mercato dell'iperplasia prostatica benigna), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/reports/70812/benign-prostatic-hyperplasia-market#request-a-sample
Our More Reports:
Fibre-Optic Gyroscope Market
https://exactitudeconsultancy.com/reports/62928/global-fibre-optic-gyroscope-market
Microcontroller Market
https://exactitudeconsultancy.com/reports/62936/global-microcontroller-market
Film Capacitor Market
https://exactitudeconsultancy.com/reports/62950/global-film-capacitor-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Benign Prostatic Hyperplasia (BPH) Market to Reach USD 18.4 Billion by 2034 here
News-ID: 4142145 • Views: …
More Releases from Exactitude Consultancy
Metastatic Prostate Cancer Market to Reach USD 17.8 Billion by 2034
Metastatic prostate cancer (mPCa) occurs when prostate cancer cells spread beyond the prostate gland to other parts of the body, commonly bones, lymph nodes, lungs, or liver. It is the most advanced and life-threatening stage of the disease, often requiring complex treatment strategies to extend survival and improve quality of life.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70810
Market Overview
The global metastatic prostate cancer market was valued at USD…
Platinum-based Chemotherapy and Nephrotoxicity Market to Reach USD 2.8 Billion b …
Platinum-based chemotherapy-primarily involving cisplatin, carboplatin, and oxaliplatin-remains a cornerstone in the treatment of various solid tumors, including lung, ovarian, testicular, and bladder cancers. These agents are highly effective due to their DNA-damaging mechanisms, but they carry significant risks, notably nephrotoxicity (kidney damage). Nephrotoxicity can manifest as acute kidney injury (AKI) or chronic kidney disease (CKD), often necessitating dose adjustments or discontinuation of therapy, impacting overall treatment outcomes.
Download Full PDF Sample…
Substance Use Disorder Market is expected to reach USD 33.4 billion by 2034
Substance Use Disorder (SUD) is a complex, chronic condition characterized by compulsive use of drugs or alcohol despite harmful consequences. It encompasses dependence on substances such as opioids, alcohol, cannabis, stimulants, and sedatives. SUD significantly impacts public health, contributing to rising healthcare costs, loss of productivity, and increased mortality rates.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70806
The SUD market includes pharmacological therapies, behavioral interventions, harm-reduction strategies, rehabilitation services,…
Opioid Use Disorder Market is expected to reach USD 6.6 billion by 2034
The OUD market encompasses pharmacological treatments, behavioral therapies, harm-reduction strategies, and rehabilitation services. Growing awareness, increased government initiatives, and the introduction of new treatment options are driving significant changes in how OUD is addressed worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70804
Market Overview
The global opioid use disorder market was valued at USD 3.7 billion in 2024 and is projected to reach USD 6.6 billion by 2034, growing at…
More Releases for BPH
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
BPH Surgical Treatment Market worth $17.19 billion in 2030
Browse 368 market data Tables and 59 Figures spread through 328 Pages and in-depth TOC on "BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030
The global [https://www.marketsandmarkets.com/Market-Reports/benign-prostatic-hyperplasia-treatment-market-198000374.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=benignprostatichyperplasiasurgicaltreatmentmarket], valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in…
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Benign Prostatic Hyperplasia (BPH) Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The benign prostatic hyperplasia (BPH) treatment market is experiencing significant growth due to the rising prevalence of BPH among the aging male…
How big is Benign Prostate Hyperplasia (BPH) Market?
Benign Prostate Hyperplasia (BPH) Market is forecasted to reach at a CAGR of 6% during the forecast period (2024-2031).
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Benign Prostate Hyperplasia (BPH) market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market…
Laser BPH Devices Market Expected to Reach $765.4 Million by 2031
Laser BPH devices market was valued at $460.25 million in 2021, and is estimated to reach $765.4 million by 2031, growing at a CAGR of 5.2% from 2022 to 2031. Prostate enlargement, commonly known as benign prostatic hyperplasia (BPH), is a noncancerous expansion of the prostate gland. Frequent urination, difficulty starting to urinate, a weak stream, the inability to urinate, or a loss of bladder control are examples of symptoms.…
